Mazdutide : Once-weekly Glucose&Weight Control

Weight Loss
In a Phase 2 trial involving 248 overweight or obese Chinese adults, Mazdutide achieved dose-dependent weight reductions of up to 11.3% from baseline after 24 weeks.
A meta-analysis confirmed significant weight loss in both diabetic and non-diabetic patients, with greater effects observed in non-diabetics and with longer treatment durations (≥24 weeks).
Glycemic Control
Significantly reduced HbA1c and fasting plasma glucose in patients with type 2 diabetes.
In the DREAMS-2 Phase 3 trial, Mazdutide demonstrated superiority over dulaglutide in both glycemic control and weight reduction in Chinese adults with T2DM.
Cardiometabolic Benefits
Improved blood pressure, lipid profiles, serum uric acid, and liver enzyme levels.
Reduced hepatic lipid accumulation, suggesting potential benefits for non-alcoholic fatty liver disease (NAFLD).
Research
Phase I / Phase II Trials
Early trials found that mazdutide was well tolerated, with dose-dependent weight loss and a side effect profile similar to other GLP-1 agonists. Common side effects included nausea, diarrhea, and upper respiratory infections

Phase II (24 Weeks)
In a randomized controlled trial among Chinese adults with overweight or obesity:

Weight loss ranged from –6.7% at 3 mg up to –11.3% at 6 mg, compared to a +1.0% increase in placebo.

A significant proportion achieved ≥5% and ≥10% weight loss; improvements were also seen in BMI, waist circumference, blood pressure, lipids, HbA1c, liver enzymes, and inflammatory markers

Phase III (GLORY-1, up to 48 Weeks)

At 48 weeks:

Mean weight reduction: –12.0% (4 mg), –14.8% (6 mg), vs –0.5% for placebo.

≥5% weight loss: 73.5% (4 mg), 82.8% (6 mg), vs 11.5%.

≥15% weight loss: 37.0% (4 mg), 50.6% (6 mg), vs 2.1%.

Liver fat dropped dramatically—–65.9% (4 mg) and –80.2% (6 mg) in patients starting with ≥10% liver fat